[:it]Fluorescent light energy: Treating rosacea subtypes 1, 2, and 3[:]

[:it]

Mario Sannino^1,4 | Giuseppe Lodi^1,4 | Markus Wied Dethlefsen² | Steven Paul Nisticò³ | Giovanni Cannarozzo⁴ | Michael Canova Engelbrecht Nielsen⁵

¹Laser Center ODS, Torre del Greco, Italy ²Fast‐Q, Frederiksberg, Denmark ³Department of Health Sciences, University of Catanzaro, Catanzaro, Italy ⁴Department of Systems Medicine, University of Tor Vergata Rome, Rome, Italy ⁵FB Dermatology Denmark Limited Aps., Ballerup, Denmark

Key Clinical Message

Kleresca® biophotonic platform utilizing fluorescent light energy effectively decreased the inflammatory and erythematous reaction common in rosacea subtypes 1, 2, and 3. Kleresca® may be considered as a single treatment for rosacea, targeting multiple features, or combined with invasive methods for an enhanced normalizing and healing profile of the skin.

KEYWORDS

biophotonic platform, chromophore, erythema, fluorescent light energy, inflammation, rosacea, subtype 1, 2, and 3

[pdfjs-viewer url=”https%3A%2F%2Fwww.gild-ftp.com%2Fwp-content%2Fuploads%2F2018%2F10%2Fccr3_1891_Rev2_EV.pdf” viewer_width=100% viewer_height=1360px fullscreen=true download=true print=true]

[:]